Martin Enwerem

TL;DR: Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions, and is safe and effective in treating MDR- and XDR-TB patients.

TL;DR: Data showed that attendance at tuberculosis centers was lower during the first 4 months of the pandemic in 2020 than for the same period in 2019.

TL;DR: The review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.

TL;DR: A debate has been initiated around the report of a severe, almost untreatable, XDR-TB case who could not access both new drugs simultaneously due to concerns about possible additive toxicity (cardiotoxicity), as well as the lack of evidence and specific guidance on their combined use.

TL;DR: South African patients with rifampicin-resistant tuberculosis (TB) and resistance to fluoroquinolones and/or injectable drugs (extensively drug-resistant (XDR) and preXDR-TB) were granted access to bedaquiline through a clinical access programme with strict inclusion and exclusion criteria.